Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Since 2014, programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have been approved by various regulatory agencies for the treatment of multiple cancers including melanoma, lung cancer, urothelial carcinoma, renal cell carcinoma, head and neck cancer, classical Hodgkin lymphoma, colorectal cancer, gastroesophageal cancer, hepatocellular cancer, and other solid tumors.
|
31584451 |
2020 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Coprimary endpoints were investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival, assessed in the intention-to-treat population and in patients with PD-L1 immune cell-positive tumours (tumours with ≥1% PD-L1 expression).
|
31786121 |
2020 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, LADs with GGO were correlated with a lower incidence of PD-L1 expression than pure-solid tumors.
|
31500267 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Purpose:</b> We conducted this study to determine the relationship between PD-1/PD-L1 inhibitors and the incidence risk of peripheral neuropathy in patients with solid tumors.
|
31552184 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recently, US Food and Drug Administration approved anti-PD-L1 immunotherapy for solid tumors with deficient mismatch repair (MMR).
|
30633926 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
|
30515672 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the response rates of anti-PD-L1 have been limited in several solid tumors.
|
31668929 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This study evaluated ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed/refractory solid tumors.
|
31230047 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Immune checkpoint inhibitors such as anti-cytotoxic T lymphocyte antigen-4 or anti-programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have demonstrated durable response rates across a broad range of solid tumors, including NSCLC, which has revolutionized the treatment of solid tumors.
|
30612418 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Our findings also suggest TET activity as a biomarker for predicting the efficacy and patient response to anti-PD-1/PD-L1 therapy, and stimulating TET activity as an adjuvant immunotherapy of solid tumors.
|
31310587 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Primary end points were ORR by Response Evaluation Criteria in Solid Tumors version 1.1 per blinded independent central review by cohort and by PD-L1 expression measured as combined positive score (CPS).
|
31046082 |
2019 |
Solid Neoplasm
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors are widely used in many types of solid tumors, and are often considered to be in the same immunotherapy subclass.
|
30698054 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
PD-1/PD-L1 expression on B cell subsets, as well as their signaling and inhibitory functions in solid tumors will be discussed in this review with the focus on how B cells expressing PD-1/PD-L1 play immunosuppressive roles in tumor progression, aiming to figure out the potential for development of diagnostic tools and new therapies involving this unique group of cells.
|
31250021 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Efficient silencing of CD47 and PD-L1 versus single gene silencing in vivo by systemic administration of LPP-P4-Ep could significantly inhibited the growth of solid tumors in subcutaneous and reduced lung metastasis in lung metastasis model.
|
30878596 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials.
|
31607917 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
KEYNOTE-028 ( ClinicalTrials.gov identifier: NCT02054806) is a nonrandomized, phase Ib trial that enrolled 475 patients with PD-L1-positive advanced solid tumors who were treated with pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity occurred.
|
30557521 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Programmed cell death ligand 1 (PD-L1) expression has been shown to associate with poor prognosis in a variety of solid tumors.
|
31143091 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Eligible patients regardless of line of therapy had measurable disease by Response Evaluation Criteria in Solid Tumors, version 1.1; Eastern Cooperative Oncology Group performance status of 0 to 1; and a representative tumor sample for assessment of immune cell (IC) PD-L1 expression.
|
30242306 |
2019 |
Solid Neoplasm
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Prespecified end points in this cohort included confirmed best overall response (per Response Evaluation Criteria In Solid Tumors, version 1.1), immune-related best overall response, duration of response, progression-free survival, overall survival, results of programmed death-ligand 1 expression-based analyses, and safety.
|
30676622 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We included all adult patients (aged ≥18) treated with anti-PD-1 or anti-PD-L1 immunotherapy for a solid tumor, diagnosed with a PNS, and registered in French pharmacovigilance databases.
|
31796119 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
|
30770348 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Meanwhile, the FDA approved PD-1/PD-L1 inhibition treatment for any solid tumor showing MSI and/or defects in the MMR system.
|
30650417 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Combination therapy with an inhibitor of indoleamine 2, 3-dioxygenase 1 (IDO1) and an agent targeting programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) is expected to be a novel and effective treatment option for various solid tumors including non-small cell lung cancer (NSCLC).
|
30642449 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BACKGROUND Targeting of PD-1/PD-L1 immune checkpoints exhibits excellent clinical outcomes in numerous types of solid tumors, including gastric cancer.
|
31519868 |
2019 |
Solid Neoplasm
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors.
|
30851544 |
2019 |